Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists

23 Jun 2021

Abstract excerpt

The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to increase platelet counts in a variety of conditions. Current indications for available TPO-RAs include treatment of chronic immune thrombocytopenia (ITP) in cases of insufficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34160821
DOI: 10.1007/s40265-021-01553-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for PharmacistsPMID 34160821Read ↗

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemSemantic proximity Read ↗

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopeniaSemantic proximity Read ↗

Role of Thrombopoietin Receptor Agonists in Inherited ThrombocytopeniaSemantic proximity Read ↗

Thrombopoietin receptor agonists in hereditary thrombocytopenias.Semantic proximity Read ↗

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysisSemantic proximity Read ↗

Hematopoietic stem cell transplant–associated thrombotic microangiopathy: review of pharmacologic treatment optionsSemantic proximity Read ↗

Immune thrombocytopenia: A review of upfront treatment strategies.Semantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.Semantic proximity Read ↗

Multicenter, Real-World Observational Study of AVA Therapy Following ELT/HET Switching in Chinese Children with Persistent/Chronic Primary ITPSemantic proximity Read ↗

Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune ThrombocytopeniaSemantic proximity Read ↗

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.